drugset / Trial / NCT01666977
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
Timeline
- Start
- 2012-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trebananib | Peptide | 15 mg/kg | Intravenous |
| Subject | Trebananib | Peptide | 30 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |